<p>The following clinically significant adverse reactions are described elsewhere in the labeling:</p>

<ul>
	<li>Increased Risk of Thrombotic Events after Premature Discontinuation</li>
	<li>Risk of Bleeding</li>
	<li>Spinal/Epidural Anesthesia or Puncture</li>
	<li>Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves</li>
	<li>Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome</li>
</ul>